~~<i id='56C4A77925'><strike id='56C4A77925'><tt id='56C4A77925'><pre id='56C4A77925'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：leisure time 2025-09-28 04:04:42 Page View：81264

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA official pushes for dedicated emerging pathogens team
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

focus

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Marvel Studios reveals new trailer for 'The Marvels': Watch here

1:56BrieLarson,TeyonahParrisandImanVellaniinascenefrom"TheMarvels."MarvelStudiosMarvelStudioshasreve

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Bird flu makes raw milk dangerous to consume, mouse study finds

JoNelAleccia/APAnewstudypublishedFridayprovidesmoreevidenceofthepotentialdangerofdrinkingunpasteuriz